Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Farmers Insurance
Teva
US Department of Justice
Cantor Fitzgerald
Medtronic
Colorcon
Accenture
Federal Trade Commission

Generated: October 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR WELLCOVORIN

« Back to Dashboard

Clinical Trials for WELLCOVORIN

Trial ID Title Status Sponsor Phase Summary
NCT00082706 Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Active, not recruiting National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving fluorouracil together with leucovorin, gemcitabine, and cisplatin works in treating patients with metastatic or unresectable adenocarcinoma of the urothelium or urachal remnant (part of the bladder).
NCT00082706 Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Active, not recruiting M.D. Anderson Cancer Center Phase 2 RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving fluorouracil together with leucovorin, gemcitabine, and cisplatin works in treating patients with metastatic or unresectable adenocarcinoma of the urothelium or urachal remnant (part of the bladder).
NCT00508872 Folfox-B Study for Patients With Colorectal Liver Metastases Terminated Sanofi Phase 2 Objective: - To evaluate the efficacy of the use of the combination of oxaliplatin, 5-fluorouracil, leucovorin and bevacizumab (FOLFOX-B) in patients with unresectable colorectal liver metastases, with the objective to downstage hepatic disease and enable complete resection of residual disease. Primary Objective: - To evaluate the resection rate in patients with initially unresectable hepatic colorectal metastases downstaged with FOLFOX-B. Complete resection of all liver lesions is the goal. Secondary Objectives: - To evaluate the probability of complete response, partial response or stable disease. - To evaluate the proportion of patients who are resected, and the proportion of patients achieving an R0 resection (among those receiving surgery). - To correlate survival with downstaging and resection based on metastatic colorectal prognostic score. - To evaluate the disease-free survival and overall survival. - To evaluate the positron emission tomography response rate. - To explore correlations of clinical response with telomerase and hTERT expression.
NCT00508872 Folfox-B Study for Patients With Colorectal Liver Metastases Terminated M.D. Anderson Cancer Center Phase 2 Objective: - To evaluate the efficacy of the use of the combination of oxaliplatin, 5-fluorouracil, leucovorin and bevacizumab (FOLFOX-B) in patients with unresectable colorectal liver metastases, with the objective to downstage hepatic disease and enable complete resection of residual disease. Primary Objective: - To evaluate the resection rate in patients with initially unresectable hepatic colorectal metastases downstaged with FOLFOX-B. Complete resection of all liver lesions is the goal. Secondary Objectives: - To evaluate the probability of complete response, partial response or stable disease. - To evaluate the proportion of patients who are resected, and the proportion of patients achieving an R0 resection (among those receiving surgery). - To correlate survival with downstaging and resection based on metastatic colorectal prognostic score. - To evaluate the disease-free survival and overall survival. - To evaluate the positron emission tomography response rate. - To explore correlations of clinical response with telomerase and hTERT expression.
NCT00515216 Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors Completed National Cancer Institute (NCI) Phase 2 This study is for patients who have stomach cancer or cancer of the lower part of the esophagus that has spread to other organs. There are many different chemotherapy treatments for this type of cancer. At the present time, there is no general agreement on the way to choose the most beneficial therapy for an individual patient. Patients with different genetic backgrounds may respond differently to the same chemotherapy treatments. In this study the investigators will use a certain genetic difference in an important gene (thymidylate synthase or TS gene) to see whether treating patients who have a particular type of that gene will respond better to a standard chemotherapy regimen. The investigators are hoping that by treating patients according to their genes, that they may respond to treatment of their cancer better and it will help the investigators choose cancer treatments better in the future.
NCT00515216 Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors Completed University of Alabama at Birmingham Phase 2 This study is for patients who have stomach cancer or cancer of the lower part of the esophagus that has spread to other organs. There are many different chemotherapy treatments for this type of cancer. At the present time, there is no general agreement on the way to choose the most beneficial therapy for an individual patient. Patients with different genetic backgrounds may respond differently to the same chemotherapy treatments. In this study the investigators will use a certain genetic difference in an important gene (thymidylate synthase or TS gene) to see whether treating patients who have a particular type of that gene will respond better to a standard chemotherapy regimen. The investigators are hoping that by treating patients according to their genes, that they may respond to treatment of their cancer better and it will help the investigators choose cancer treatments better in the future.
NCT00515216 Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors Completed University of North Carolina Phase 2 This study is for patients who have stomach cancer or cancer of the lower part of the esophagus that has spread to other organs. There are many different chemotherapy treatments for this type of cancer. At the present time, there is no general agreement on the way to choose the most beneficial therapy for an individual patient. Patients with different genetic backgrounds may respond differently to the same chemotherapy treatments. In this study the investigators will use a certain genetic difference in an important gene (thymidylate synthase or TS gene) to see whether treating patients who have a particular type of that gene will respond better to a standard chemotherapy regimen. The investigators are hoping that by treating patients according to their genes, that they may respond to treatment of their cancer better and it will help the investigators choose cancer treatments better in the future.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for WELLCOVORIN

Condition Name

Condition Name for WELLCOVORIN
Intervention Trials
Leukemia 4
Acute Lymphoblastic Leukemia 2
Stage IVB Colorectal Cancer AJCC v7 2
Stage IVA Colorectal Cancer AJCC v7 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for WELLCOVORIN
Intervention Trials
Leukemia 5
Adenocarcinoma 5
Colorectal Neoplasms 5
Precursor Cell Lymphoblastic Leukemia-Lymphoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for WELLCOVORIN

Trials by Country

Trials by Country for WELLCOVORIN
Location Trials
United States 34
Italy 4
Australia 4
Belgium 1
New Zealand 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for WELLCOVORIN
Location Trials
Texas 11
Missouri 3
Pennsylvania 2
Florida 2
North Carolina 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for WELLCOVORIN

Clinical Trial Phase

Clinical Trial Phase for WELLCOVORIN
Clinical Trial Phase Trials
Phase 3 2
Phase 2 11
Phase 1/Phase 2 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for WELLCOVORIN
Clinical Trial Phase Trials
Recruiting 7
Completed 4
Not yet recruiting 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for WELLCOVORIN

Sponsor Name

Sponsor Name for WELLCOVORIN
Sponsor Trials
M.D. Anderson Cancer Center 12
National Cancer Institute (NCI) 5
Washington University School of Medicine 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for WELLCOVORIN
Sponsor Trials
Other 24
Industry 12
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Covington
Johnson and Johnson
UBS
Cerilliant
Fuji
Queensland Health
Cipla
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.